Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This trial will be a randomized controlled single-center pilot trial comparing the use of
angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with
persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of
the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to
angiotensin II. Given our angiotensin II will be compared to SOC, this will be an unblinded
study.